Prevention of recurrent severe hypoglycaemia: optimised multiple daily insulin injection (MDI) versus continuous subcutaneous insulin infusion (CSII) with or without adjunctive real-time continuous glucose monitoring

ISRCTN ISRCTN52164803
DOI https://doi.org/10.1186/ISRCTN52164803
EudraCT/CTIS number 2009-015396-27
Secondary identifying numbers 5052
Submission date
06/08/2009
Registration date
18/09/2009
Last edited
30/03/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
People with type 1 diabetes often miss early warnings of falling blood glucose level. This is a major concern as it can cause the individual to collapse without warning (severe hypoglycaemia). This problem can be reversed by preventing glucose levels falling too low, but this can be difficult as high glucose levels can also be damaging. Severe hypoglycaemia can be prevented in most people while improving overall glucose control using modern insulin injections or an insulin pump. In this study, we plan to further test these treatments with a new glucose sensor which can detect low glucose levels. The aim of the study is to find the best way of managing and supporting all patients with hypoglycaemia in the future.

Who can participate?
Male or female participants aged between 18 and 74 years, who have type 1 diabetes mellitus and have experienced impaired hypoglycaemia awareness and have experienced an episode of severe hypoglycaemia.

What does the study involve?
The study will compare insulin pumps and multiple daily injections with or without continuous glucose monitoring. Participants are randomly allocated to receiving either multiple daily insulin injections or insulin pump therapy, with or without continuous glucose monitoring.

What are the possible benefits and risks of participating?
The education programme given is hoped to improve the participants' overall diabetes control for many years after the end of the study. Participants with impaired awareness of hypoglycaemia may be at risk of severe hypoglycaemia. However, all the study treatments are tailored towards strict hypoglycaemia avoidance. For participants receiving insulin pump therapy may be at risk of diabetic ketoacidosis if the insulin pump is not used correctly.

Where is the study run from?
Newcastle Upon Tyne Hospitals NHS Foundation Trust

When is the study starting and how long is it expected to run for?
The study began recruiting participants in 2010, and recruitment ended in June 2011. The study will be completed in August 2013.

Who is funding the study?
Diabetes UK

Who is the main contact?
Professor James Shaw
jim.shaw@ncl.ac.uk

Contact information

Prof James Shaw
Scientific

Professor of Regenerative Medicine for Diabetes and Honorary Consultant Physician
Institute of Cellular Medicine
4th Floor William Leech Building
Newcastle University
Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
United Kingdom

Email jim.shaw@ncl.ac.uk

Study information

Study designInterventional multicentre randomised controlled trial, 2 x 2 factorial design
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details found in the intervention section below to request a patient information sheet
Scientific titleA definitive randomised controlled trial (RCT) comparing optimised multiple daily insulin injection (MDI) and continuous subcutaneous insulin infusion (CSII) with or without adjunctive real-time continuous glucose monitoring for the prevention of recurrent severe hypoglycaemia
Study acronymhypo COMPASS
Study objectivesThis study asks whether, in people who have diabetes mellitus and suffer from impaired or altered awareness of low blood sugars (hypoglycaemia), it is possible to restore that awareness and therefore prevent severe hypoglycaemia by rigorously preventing the participants from having any episodes of hypoglycaemia without jeopardising their overall diabetes control and using existing technology. The study will be able to answer this by analysis of a validated quantitative questionnaire that will be used throughout the study.

Please note that as of 25/10/2012, the anticipated end date for this study was updated from 31/07/2012 to 31/08/2013.
Ethics approval(s)Sunderland Research Ethics Committee,18/12/2009, ref: 09/H0904/63
Health condition(s) or problem(s) studiedType 1 diabetes mellitus
InterventionAll participants will participate in an educational programme which has been validated in our single centre pilot study. This includes carbohydrate counting, discussion on glycaemic indices of food, the effect of exercise on blood glucose, the importance of detection and prevention of nocturnal hypoglycaemia and recommendations on carbohydrate administration for blood glucose less then 4 mmol/l. Thereafter participants will be randomised to one of four intervention groups for the 24 week intervention period. The four groups are as follows:
1. Multiple daily subcutaneous insulin analogue injections (MDI). Insulins used will be insulin glargine and insulin aspart.
2. MDI using aspart and glargine with real time continuous glucose monitoring
3. Continuous subcutaneous insulin infusion (CSII) using insulin aspart
4. CSII using insulin aspart with real time continuous glucose monitoring

Participants will be followed up monthly during the 24 week intervention period after which they will be followed up at 6, 12 and 18 months. All diabetes care after the 24 week intervention period will return to routine NHS care.

Contact details for Patient Information Sheet:
Cath Brennand
Clinical Trial Manager
Newcastle Clinical Trials Unit
4th Floor, William Leech Building
Medical School
Framlington Place
Newcastle upon Tyne NE2 4HH
United Kingdom
Email: cath.brennand@newcastle.ac.uk
Intervention typeOther
Primary outcome measureRestoration of hypoglycaemia awareness as determined by quantitative questionnaire analysis.
Secondary outcome measures1. Difference in rates of mild symptomatic hypoglycaemia as measured by home blood glucose diaries at 6 months and intermediate study visits
2. Difference in duration of biochemical hypoglycaemia determined by 7-day continuous glucose monitoring system (CGMS) at 6 months and intermediate study visits
3. Difference in HbA1c at 6 months and intermediate study visits
4. Difference in rates weekly 8-point glucose profiles
Overall study start date01/12/2009
Completion date31/08/2013

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants100 patients
Key inclusion criteria1. Male or female patients aged 18 - 74 years
2. Established type 1 diabetes mellitus (C peptide negative)
3. Experienced impaired hypoglycaemia awareness and, or at least one episode of severe hypoglycaemia as defined as by the American Diabetes Association in the previous 12 months
4. Willing to undergo intensive insulin therapy including the use of CSII (insulin pump)
5. Willing to monitor home blood glucose levels at least four times daily
6. Willing to monitor and record signs and symptoms of hypoglycaemia
Key exclusion criteria1. Not willing to consider insulin pump therapy
2. Unable to use the technology such as real time glucose monitoring
Date of first enrolment01/01/2010
Date of final enrolment01/06/2011

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Institute of Cellular Medicine
Newcastle upon Tyne
NE2 4HH
United Kingdom

Sponsor information

Newcastle Upon Tyne Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre

c/o Amanda Tortice
Research and Development
Newcastle upon Tyne
NE14LP
England
United Kingdom

Phone +44 (0)191 282 5959
Email amanda.tortice@nuth.nhs.uk
Website http://www.newcastle-hospitals.org.uk/
ROR logo "ROR" https://ror.org/05p40t847

Funders

Funder type

Charity

Diabetes UK (UK) (ref: 07/0003556)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
DIABETES UK LIMITED, British Diabetic Association
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 13/12/2012 Yes No
Results article results 01/12/2013 Yes No
Results article results 01/08/2018 Yes No
Results article results 20/12/2022 30/03/2023 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

30/03/2023: Publication reference added.
21/09/2018: Publication reference added